| Literature DB >> 21504594 |
Parasto Mirzaagha1, Marie Louie, Ranjana Sharma, L Jay Yanke, Ed Topp, Tim A McAllister.
Abstract
BACKGROUND: Feedlot cattle in North America are routinely fed subtherapeutic levels of antimicrobials to prevent disease and improve the efficiency of growth. This practice has been shown to promote antimicrobial resistance (AMR) in subpopulations of intestinal microflora including Escherichia coli. To date, studies of AMR in feedlot production settings have rarely employed selective isolation, therefore yielding too few AMR isolates to enable characterization of the emergence and nature of AMR in E. coli as an indicator bacterium. E. coli isolates (n = 531) were recovered from 140 cattle that were housed (10 animals/pen) in 14 pens and received no dietary antimicrobials (control--5 pens, CON), or were intermittently administered subtherapeutic levels of chlortetracycline (5 pens-T), chlortetracycline + sulfamethazine (4 pens-TS), or virginiamycin (5 pens-V) for two separate periods over a 9-month feeding period. Phenotype and genotype of the isolates were determined by susceptibility testing and pulsed field gel electrophoresis and distribution of characterized isolates among housed cattle reported. It was hypothesized that the feeding of subtherapeutic antibiotics would increase the isolation of distinct genotypes of AMR E. coli from cattle.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21504594 PMCID: PMC3103423 DOI: 10.1186/1471-2180-11-78
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Figure 1Feeding and antibiotic administration timeline. Numbers indicate day of the feeding period and B, C, D, and E represent points where fecal samples were collected from cattle. Silage-based diets were fed for 115 d, followed by 21 d of transition to the grain-based diet, which was then fed until shipment of cattle to market. Shaded areas indicate the periods that antimicrobials were included in the diet.
Distribution of isolates characterized in this study
| Number of animals | Total | ||||||
|---|---|---|---|---|---|---|---|
| B | C | D | E | ||||
| CON | MC | 5 | 5 | 5 | 5 | 5 | 20 |
| MT | 50 | 15 | 19 | 47 | 30 | 111 | |
| MA | 50 | 0 | 8 | 1 | 17 | 26 | |
| T | MC | 3 | 3 | 3 | 2 | 3 | 11 |
| MT | 30 | 12 | 10 | 27 | 25 | 74 | |
| MA | 30 | 2 | 0 | 1 | 10 | 13 | |
| TS | MC | 3 | 3 | 3 | 3 | 3 | 12 |
| MT | 30 | 23 | 26 | 29 | 29 | 107 | |
| MA | 30 | 15 | 14 | 7 | 15 | 51 | |
| V | MC | 3 | 3 | 3 | 3 | 3 | 12 |
| MT | 30 | 11 | 6 | 25 | 27 | 69 | |
| MA | 30 | 2 | 2 | 5 | 16 | 25 | |
a Steers were fed no antibiotics (control, CON), or chlortetracycline and sulfamethazine (44 ppm; TS); chlortetracycline (11 ppm; T) or virginiamycin (31 ppm; V) administered in two discrete periods (see Figure 1).
b Isolates were collected by plating fecal slurries onto (i) MacConkey agar (MAC) containing no antibiotics (control, MC), or amended with tetracycline hydrochloride (4 μg/mL; MT) or with ampicillin (50 μg/mL; MA).
c Sampling days occurred during each of the four phases of the feeding trial (see Figure 1).
Primers used in assay of isolates for resistance determinants
| Gene | Amplicon size (bp) | Genbank accession no. | Control plasmid/gDNA | Source of plasmid and reference | |
|---|---|---|---|---|---|
| GCT ACA TCC TGC TTG CCT TC | 210 | pSL18 | [ | ||
| CAT AGA TCG CCG TGA AGA GG | |||||
| TTG GTT AGG GGC AAG TTT TG | 659 | pRT11 | [ | ||
| GTA ATG GGC CAA TAA CAC CG | |||||
| CTT GAG AGC CTT CAA CCC AG | 418 | pBR322 | [ | ||
| ATG GTC GTC ATC TAC CTG CC | |||||
| AAA CCA TTA CGG CAT TCT GC | 787 | pSL106 | [ | ||
| GAC CGG ATA CAC CAT CCA TC | |||||
| AAA CCA CAT CCT CCA TAC GC | 278 | pSL1504 | [ | ||
| AAA TAG GCC ACA ACC GTC AG | |||||
| GCT CGG TGG TAT CTC TGC TC | 468 | pJA8122 | [ | ||
| AGC AAC AGA ATC GGG AAC AC | |||||
| TCG ATA GGA ACA GCA GTA | 169 | PAT102 | [ | ||
| CAG CAG ATC CTA CTC CTT | |||||
| TCG TTA GCG TGC TGT CAT TC | 267 | pVB.A15 | [ | ||
| GTA TCC CAC CAA TGT AGC CG | |||||
| GTG GAC AAA GGT ACA ACG AG | 406 | pJ13 | [ | ||
| CGG TAA AGT TCG TCA CAC AC | |||||
| AAC TTA GGC ATT CTG GCT CAC | 515 | pUOA1 | Taylorb | ||
| TCC CAC TGT TCC ATA TCG TCA | |||||
| CAT AGA CAA GCC GTT GAC C | 667 | pAT451 | Mulvey | ||
| ATG TTT TTG GAA CGC CAG AG | |||||
| CTT GGA TTG CGG AAG AAG AG | 676 | pJIR39 | Monash Universityc | ||
| ATA TGC CCA TTT AAC CAC GC | |||||
| TTA TAC TTC CTC CGG CAT CG | 904 | pNFD13-2 | Salyersd | ||
| ATC GGT TCG AGA ATG TCC AC | |||||
| CAA TAA TTG GTG GTG GAC CC | 468 | pBS5 | [ | ||
| TTC TTA CCT TGG ACA TCC CG | |||||
| CGC TTC CCG TTA ACA AGT AC | 419 | SU01 | [ | ||
| CTG GTT CAT TTC AGA TAG CG | gDNA | ||||
| AGC AGC GCC AGT GCA TCA | 708 | SU05 | [ | ||
| ATT CGA CCC CAA GTT TCC | gDNA | ||||
| TTG GGT GCA CGA GTG GGT | 503 | SU07 | [ | ||
| TAA TTG TTG CCG GGA AGC | gDNA |
a Primers selected from previously published source [26,26].
b Provided by Dr.Taylor (University of Alberta, Edmonton, AB, Canada).
c Provided by the Monash University (Victoria, Australia).
d Provided by Dr. Salyers (University of Illinois, Urbana, USA).
Total number (n) and percentage of phenotype observed within isolates recovered from MacConkey agar amended with 4 μg/ml tetracycline hydrochloride after diet administration of control and three antimicrobial treatments.
| AMP | 6.3b (7) | 2.7c (2) | 18.7a (20) | 13.0b (9) |
| STR | 52.3a (58) | 35.1b,c (26) | 32.7b (35) | 50.7a (35) |
| SMX | 42.3c (47) | 47.3b,c (35) | 55.1a (59) | 42.0b (29) |
| TE | 99.1ba (110) | 100a (74) | 100a (107) | 98.6b (68) |
| 111 | 74 | 107 | 69 | |
†CON; no antibiotics added to supplement, T: chlortetracycline provided as Aureomycin 100-G fed at 11 ppm, TS: chlortetracycline + sulfamethazine, provided as Aureo S-700G (Alpharma Inc.) fed at 44 ppm and V: virginiamycin provided as V-Maxed at 31 ppm.
Total number (n) and percentage of phenotype observed within isolates recovered from MacConkey agar amended with 50 μg/ml ampicillin after diet administration of control and three antimicrobial treatments.
| AMP | 100 (26) | 100 (13) | 100 (51) | 100 (25) |
| CL | 61.5a (16) | 15.4b (2) | 5.9b (3) | 4.0b (1) |
| STR | 38.5 (10) | 23.1 (3) | 13.7 (7) | 40.0 (10) |
| TE | 38.5c (10) | 76.9b (10) | 94.1a (48) | 56c (14) |
| 26 | 13 | 51 | 25 | |
† CON; no antibiotics added to supplement, T: chlortetracycline provided as Aureomycin 100-G fed at 11 ppm, TS: chlortetracycline + sulfamethazine, provided as Aureo S-700G (Alpharma Inc.) fed at 44 ppm and V: virginiamycin provided as V-Maxed at 31 ppm.
Figure 2Antibiogram and PFGE types of fecal . Sampling days (B to E) are depicted in Figure 1. Each box represents a single isolate from a particular steer on a given sampling day. The first eight colors represent the most commonly observed antibiogram patterns with grey indicating an infrequently observed antibiogram. Unfilled boxes indicate no isolate obtained on MT. Common letters indicate isolates with >90% genetic homology. Shaded boxes without a letter indicate isolates with <90% genetic homology with antibiogram data. Dietary treatments were as follows: Control: no antibiotics; Chlortetracycline (11 ppm; denoted T); Chlortetracycline + sulfamethazine (44 ppm; denoted TS); and Virginiamycin (31 ppm; V). nc: isolates not characterized.
Figure 3Antibiogram and PFGE types of fecal . Sampling days (B to E) are depicted in Figure 1. Each box represents a single isolate from a particular steer on a given sampling day. The first eight colors represent the most commonly observed antibiogram patterns and grey indicates an infrequently observed antibiogram. Unfilled boxes indicate no isolate was obtained on MA. Common letters indicate isolates with >90% genetic homology. Shaded boxes without a letter indicate isolates with <90% genetic homology with antibiogram data. Dietary treatments were as follows: Control: no antibiotics; Chlortetracycline (11 ppm; denoted T); Chlortetracycline + sulfamethazine (44 ppm; denoted TS); and Virginiamycin (31 ppm; V).